Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - ferric hydroxide sucrose compound - unknown - ferric hydroxide sucrose compound ungrouped active 0.0 - active constituent

Australija - anglų - Department of Health (Therapeutic Goods Administration)

factors group australia pty ltd - ferric pyrophosphate, quantity: 38.75 mg (equivalent: iron, qty 10 mg) - tablet, chewable - excipient ingredients: maltodextrin; sorbitol; colloidal anhydrous silica; purified talc; lecithin; xylitol; sodium chloride; stearic acid; citric acid; flavour - maintain/support energy levels ; maintain/support energy production ; relieve weariness/tiredness/fatigue/feeling of weakness ; aid/assist healthy red blood cell production ; maintain/support red blood cell health

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

actavis pharma, inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. - known hypersensitivity to sodium ferric gluconate or any of its components. pregnancy category b there are no adequate and well-controlled studies with sodium ferric gluconate complex in sucrose injection in pregnant women. reproduction studies have been performed in mice at doses up to 100 mg/kg/day (300 mg/m2 /day) and in rats at up to 20 mg/kg/day (120 mg/m2 /day). the doses in mice and rats are 4 and 1.5 times the human dose of 125 mg/day (77 mg/m2 /day) on a body surface area basis and have revealed no evidence of harm to the fetus due to sodium ferric gluconate complex in sucrose injection. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly need

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

actavis pharma, inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. - known hypersensitivity to sodium ferric gluconate or any of its components. pregnancy category b there are no adequate and well-controlled studies with sodium ferric gluconate complex in sucrose injection in pregnant women. reproduction studies have been performed in mice at doses up to 100 mg/kg/day (300 mg/m2 /day) and in rats at up to 20 mg/kg/day (120 mg/m2 /day). the doses in mice and rats are 4 and 1.5 times the human dose of 125 mg/day (77 mg/m2 /day) on a body surface area basis and have revealed no evidence of harm to the fetus due to sodium ferric gluconate complex in sucrose injection. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly ne

Australija - anglų - Department of Health (Therapeutic Goods Administration)

factors group australia pty ltd - ferric pyrophosphate, quantity: 38.75 mg (equivalent: iron, qty 10 mg) - tablet, chewable - excipient ingredients: maltodextrin; sodium chloride; sorbitol; xylitol; stearic acid; citric acid; colloidal anhydrous silica; purified talc; lecithin; flavour - maintain/support energy levels ; maintain/support energy production ; relieve weariness/tiredness/fatigue/feeling of weakness ; maintain/support general health and wellbeing ; aid/assist healthy red blood cell production ; maintain/support red blood cell health ; maintain/support blood health ; helps maintain/support transport of oxygen in the body ; helps maintain/support haemoglobin formation/synthesis ; maintain/support immune system health ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support cognitive function/mental function

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pentavite pty ltd - ferric pyrophosphate, quantity: 53.368899999999996 mg/g (equivalent: iron, qty 16 mg/g) - powder - excipient ingredients: beetroot; dextrin; lecithin; sodium chloride; maltodextrin; sorbitol; xylitol - maintain/support energy levels ; maintain/support energy production ; maintain/support general health and wellbeing ; aid/assist healthy red blood cell production ; maintain/support blood health ; helps maintain/support transport of oxygen in the body ; aid/assist/helps oxygen transport to body tissues ; helps maintain/support haemoglobin formation/synthesis ; maintain/support immune system health ; maintain/support healthy immune system function ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; aid/assist/helps synthesis of neurotransmitters

Australija - anglų - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - ferric pyrophosphate, quantity: 3.48 mg/ml (equivalent: iron, qty 1 mg/ml); lysine hydrochloride, quantity: 30 mg/ml; thiamine hydrochloride, quantity: 1 mg/ml; pyridoxine hydrochloride, quantity: 500 microgram/ml (equivalent: pyridoxine, qty 410 microgram/ml); cyanocobalamin, quantity: 2.5 microgram/ml - oral liquid - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); ethanol; sodium hydroxide; purified water; hydrochloric acid; sodium benzoate; amaranth; glycerol; sodium citrate dihydrate; sorbic acid; flavour - helps convert (state food) into energy ; maintain/support body metabolism/metabolic rate ; maintain/support healthy growth and development ; maintain/support general health and wellbeing ; maintain/support blood health ; helps maintain/support transport of oxygen in the body ; aid/assist/helps oxygen transport to body tissues ; helps enhance/promote/increase absorption of dietary (state vitamin/mineral/nutrient) ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support (state vitamin/mineral) within normal range

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

ropack inc. - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - ferric cation 272 mg in 272 mg - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data with triferic use in pregnant women to inform a drug-associated risk. no teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (mrhd) of 27.2 mg per dialysis [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, the maternally toxic ferric pyrophosphate citra

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

rockwell medical, inc - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - ferric cation 5.44 mg in 1 ml - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data with triferic use in pregnant women to inform a drug-associated risk. no teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (mrhd) of 27.2 mg per dialysis [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, the maternally toxic ferric py

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

american regent, inc. - ferric carboxymaltose (unii: 6897gxd6oe) (ferric cation - unii:91o4lml611) - ferric cation 50 mg in 1 ml - injectafer is indicated for the treatment of: •     iron deficiency anemia (ida) in: - adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. - adult patients who have non-dialysis dependent chronic kidney disease. adult patients who have non-dialysis dependent chronic kidney disease. •     iron deficiency in adult patients with heart failure and new york heart association class ii/iii to improve exercise capacity. injectafer is contraindicated in patients with a history of hypersensitivity to injectafer or any of its components [see warnings and precautions (5.1) ]. risk summary parenteral iron administration may be associated with hypersensitivity reactions [ see warnings and precautions (5.1)], which may have serious consequences, such as fetal bradycardia (see clinical considerations ). advise pregnant wome